The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

[7] Among men with both DO and BOO that did not improve on alpha-blocker monotherapy, 73% did show symptomatic improvement after 3 months of tolterodine treatment. Urge urinary incontinence ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Treatment with vibegron reduced the ... approval of Gemtesa is an important milestone for the men with unresolved symptoms of OAB while being treated for BPH, which underscores our urgency to ...

Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...

OAB can significantly impact quality of life; it can impact physical functioning, sexual function and social interactions. The standard treatments for overactive bladder include lifestyle changes ...

When an overactive bladder is affecting your daily life, this might be just the time to look into treatment options. I'm Joy Behar. And I'm talking with an expert on OAB about how to solve this ...

To observe this 63-year-old grandmother you'd never know she has incontinence ... lifestyle changes and medications don't help, other treatments such as electrical stimulation and surgery may ...

Many people believe that urinary tract infections (UTIs) and incontinence are more common in women, but they can also affect ...

Imbrium Therapeutics L.P. ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), announced results from a Phase 1b clinical signal detection study evaluating the safety and efficacy of the novel ...